RxDoctor Payments Data

Daniel Hexter, MD

Neurology · Annapolis, MDNPI 1942224753

Payments from drug & device makers

$34,781in general payments, 2019–2025

Across 2,022 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Biogen$3K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Amgen$2K
  • Pfizer$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$790%
  • Food & beverage$34,35199%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)448$5,736
Biogen217$3,416
Novartis166$2,358
Teva Pharmaceuticals USA, Inc.95$1,973
Amgen(2 entities)104$1,886
Pfizer81$1,367
Genentech USA, Inc.67$1,283
Lilly USA, LLC68$1,131
CSL Behring51$1,079
UCB, Inc.45$1,008
Argenx US, Inc.45$946
Grifols USA, LLC47$865
Neurocrine Biosciences, Inc.35$814
AstraZeneca(2 entities)30$621
Amneal Pharmaceuticals LLC29$555
Sanofi25$470
Lundbeck LLC23$467
EMD Serono, Inc.22$448
Sunovion Pharmaceuticals Inc.30$442
Kyowa Kirin, Inc.21$440
Bristol Myers Squibb22$428
Eisai Inc.17$354
Takeda Pharmaceuticals U.S.A., Inc.11$343
Biohaven Pharmaceuticals, Inc.23$328
Merz Pharmaceuticals, LLC12$318
Acadia Pharmaceuticals Inc14$306
Alnylam Pharmaceuticals Inc.11$270
Biohaven Pharmaceutical Holding Company Ltd.29$266
Catalyst Pharmaceuticals, Inc.10$259
Greenwich Biosciences, Inc.13$257
Supernus Pharmaceuticals, Inc.12$245
Neurelis, Inc.12$245
Octapharma USA, Inc.11$240
Tanabe Pharma America, Inc.10$227
Banner Life Sciences, LLC11$226
Avanir Pharmaceuticals, Inc.18$217
TG Therapeutics, Inc.9$207
Ipsen Biopharmaceuticals, Inc10$196
Adamas Pharmaceuticals, Inc.10$178
MDD US Operations, LLC4$142
Mallinckrodt Enterprises LLC5$136
Acorda Therapeutics, Inc7$132
Johnson & Johnson6$130
E.r. Squibb & Sons, L.L.C.6$116
Merz North America, Inc.4$109
Axsome Therapeutics, Inc.4$103
Promius Pharma LLC3$78
Upsher-smith Laboratories LLC4$74
Akcea Therapeutics, Inc.1$72
Revance Therapeutics, Inc.4$71
GE HealthCare2$70
Aquestive Therapeutics, Inc.3$69
Sanofi-aventis U.S. LLC3$68
SK Life Science, Inc.3$68
Scilex Pharmaceuticals Inc.3$57
Bio Products Laboratory USA, Inc.3$56
Vanda Pharmaceuticals Inc.2$54
Livanova USA, Inc.1$49
Otsuka America Pharmaceutical, Inc.2$48
Avion Pharmaceuticals3$46

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,781 in reported general payments places this provider in the 80th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$2,956,761
Medicare patients
546
Services billed
82,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4629$415,855
Gamunex-CImmune Globul G/Gly/Iga Avg 4629$296,389
IngrezzaValbenazine Tosylate22$172,054
FingolimodFingolimod Hcl11$79,396
AptiomEslicarbazepine Acetate19$64,053
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$56,466
Emgality PenGalcanezumab-Gnlm29$30,188
UbrelvyUbrogepant14$21,361
BotoxOnabotulinumtoxina14$17,093
Glatiramer Acetate12$16,654
Mycophenolate Mofetil47$10,233
Rivastigmine32$8,904
Gabapentin294$6,342
Dalfampridine ErDalfampridine20$6,258
Pyridostigmine Bromide60$5,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$865$296,38929 claims
Neurocrine Biosciences, Inc.Ingrezza$814$172,05422 claims
Sunovion Pharmaceuticals Inc.Aptiom$442$64,05319 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$343$56,46618 claims
AbbVieUbrelvy, Botox$5,736$38,45528 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$555$15,353107 claims
Upsher-smith Laboratories LLCTopiramate$74$48540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 neurology providers in Maryland.

Other neurology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →